Treatment for telangiectasias and reticular veins

Nakano, Luis Cu; Cacione, Daniel G; Baptista-Silva, Jose CC; Flumignan, Ronald Luiz Gomes

doi:10.1002/14651858.cd012723.pub2

Cited by 17 publications

(9 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By analyzing the differences between different sclerosants, a Cochrane review found no evidence to suggest superior efficacy or increased patient satisfaction with any sclerosant. 8,9 However, STS was associated with more hyperpigmentation, matting, and probably more pain. 9 Although, STS concentration in most studies was more than 0.2%: Leach BC et al, 10 Lupton JR et al, 11 Peterson JD et al, 12 and Rao J et al 13 used STS 0.25%; Carlin MC et al 14 and Goldman MP 15 used STS 0.5%; and Rabe E et al 16 used STS 1% for treating telangiectasias.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 However, STS was associated with more hyperpigmentation, matting, and probably more pain. 9 Although, STS concentration in most studies was more than 0.2%: Leach BC et al, 10 Lupton JR et al, 11 Peterson JD et al, 12 and Rao J et al 13 used STS 0.25%; Carlin MC et al 14 and Goldman MP 15 used STS 0.5%; and Rabe E et al 16 used STS 1% for treating telangiectasias. In their histological study, Bush R and Bush P 6 observed that with STS concentration >0.2%, muscle wall alterations were marked and, in some cases, considerable wall thinning was noted.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial

et al. 2023

View full text Add to dashboard Cite

Objectives This study aimed to compare telangiectasias disappearance after sclerotherapy with hypertonic glucose (HG) and different concentrations of sodium tetradecyl sulfate (STS). Methods Women aged 18–70 years with telangiectasias were included. The primary efficacy endpoint was telangiectasia disappearance. The clearing of vessels was assessed using a six-point scale (from 0 to 5). Results A total of 116 women completed an 8-week follow-up: 31, 27, 25, and 33 were in the HG 75%, STS 0.05%, STS 0.1%, and STS 0.15% groups, respectively. The median score of vein disappearance was significantly lower in the STS 0.05% (3, 0.25–4), STS 0.1% (3, 1.25–4), and STS 0.15% (4, 2–4) groups than in the HG group (4, 3–5) after 56 days, p = .00002. Conclusion Sclerotherapy of telangiectasias with 75% HG showed significantly better results than low concentrations of STS. Trial registration ClinicalTrials.gov NCT04132323.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Sclerotherapy is the first‐line therapy. Data present in the literature demonstrate that normally with sclerotherapy, clearance after one treatment varies from 50% to 84% of patients 8 . Also the data show that, to achieve full clearance, up to six treatments may be needed 9 …”

Section: Discussionmentioning

confidence: 99%

980 nm laser endo‐perivenous treatment of lower limb reticular veins and telangiectasias. Technical notes

PALOMBI¹,

Morelli

2023

Lasers Surg Med

View full text Add to dashboard Cite

Introduction: For several years, the venous aesthetic problem has been tackled mainly with sclerotherapy techniques. In recent years, laser techniques have been added, both surface (transdermal) and endo-perivenous, performed with small optical fibers (100-200 μm) and low intensities in terms of LEED and Watt. The endo-perivenous technique has extended the possibilities of laser treatment also to the nourishing veins, to telangiectasias resistant to therapies with sclerosing agents and/or transdermal lasers and to vessels with larger diameters (1-3 mm) and depths >1.3 mm. Materials and Methods: We report a series of 20 patients affected by reticular veins and telangiectasias of the lower limbs (CEAP C1-2) treated with endoperivenous technique. The most used setting was: 3 W (range: 2-4 W) with a mean fluence delivered of 11.25 J/cm (range: 6-18) in pulse mode with 980 nm laser, 200 μm fiber after a preventive skin cooling. Scheduled follow-up occurred 20 and 60 days after treatment. Results: Total technical success, understood as complete obliteration of all treated vessels, was achieved in 70% of cases (14/20) after just one treatment. The most observed early local complications were erythema, vesicles, and small cutaneous eschars that regressed in 3 weeks. At 60-day follow-up, just one complication was observed: a small area of hyperpigmentation (5%). In this case, chemical peel procedures was performed with good clinical results. Conclusions: Endoperivenous laser treatment represents an effective and valid tool for the treatment of teleangectasias and reticular varicose veins.

show abstract

“…Treatments include sclerotherapy, laser therapy, intense pulsed light treatment, microphlebectomy, and thermocoagulation 4 . The most common is sclerotherapy, a nonsurgical procedure in which the physician injects a sclerosant, which causes endothelial damage, blockage of the vein, and subsequent fibrosis 5 …”

Section: Introductionmentioning

confidence: 99%

Case report: Novel leg vein treatment CLaCS guided by augmented reality 11 years follow‐up

Miyake,

Grill,

Feitoza

2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Telangiectasias is most prevalent on the lower limbs and has been estimated to manifest in 40%–90% of the population. Treatments for telangiectasias include sclerotherapy, laser therapy, intense pulsed light treatment, microphlebectomy, and thermocoagulation. Cryo‐Laser & Cryo‐Sclerotherapy (CLaCS) effectively combines thermal and injection sclerotherapy. In this treatment, unwanted veins are targeted by a transdermal laser and immediately receive injection sclerotherapy. During the whole procedure, an air‐cooling device (Cryo) blows onto the surrounding skin and tissue to prevent skin burn. Here, we present a case report of a challenging telangiectasias treated with ClaCS.

show abstract

Treatment for telangiectasias and reticular veins

Cited by 17 publications

References 72 publications

Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial

Low concentration of sodium tetradecyl sulfate and hypertonic glucose solution for the treatment of telangiectasia: A prospective randomized clinical trial

980 nm laser endo‐perivenous treatment of lower limb reticular veins and telangiectasias. Technical notes

Case report: Novel leg vein treatment CLaCS guided by augmented reality 11 years follow‐up

Contact Info

Product

Resources

About